Philadelphia-based scientists have received permission to attempt to revive brain dead patients in an undisclosed Latin American country.
A company called Bioquark is determined to revive brain dead patients using techniques such as stem cell therapy, laser therapy, and electrical stimulation. Their web-site gives the impression that they are close to being able to cure many diseases, reverse aging and even resurrect the dead.
Furthermore, an unnamed country in Latin America has just given the go-ahead for clinical trials of the techniques to take place. Previously, the US and India have halted their efforts due to bioethical questions. 20 patients in India were lined up by Bioquark and their Indian collaborators Revita Life Sciences. However, only six months later the Indian Drug Controller General shut them down.
CEO, Ira Pastor, explained that the process would be broken down into stages. Currently, the company is focusing only on the first stage, which they have named the Reanima Project. Their intention with this first round of clinical trials is to “explore technical boundaries of life and death to offer patients and families a 2nd chance.”
The above statement would surely fill grieving loved ones with hope if Bioquark can deliver what they claim. Especially as they have bypassed any animal testing of the techniques.
Firstly, scientists will inject patients with a quantity of the patient’s own stem cells. Next, they will inject a peptide formula into their spinal column. With this technique the hope to incite neurons to begin to regrow.
Thirdly, they use electrical stimulation to attempt to encourage nerve activity. Lastly, transcranial laser devices will be utilized for around 15 days to inspire new neural connections to form. During this time Researchers will observe the patients to see if any activity occurs on the EEG, or they exhibit any “life” behaviors.
Skeptics and ethics
While it sounds like bringing dead loved ones back to life would be a marvelous thing, there are in fact many ethical considerations that Bioquark are overlooking.
Keep reading …